Urodynamix Technologies Ltd.
TSX VENTURE : URO

Urodynamix Technologies Ltd.

October 09, 2008 09:00 ET

Urodynamix Announces Publication of Two Articles in Canadian Journal of Urology

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Oct. 9, 2008) - Urodynamix Technologies Ltd. (TSX VENTURE:URO) today announced that two peer-reviewed articles related to the application of its near infrared spectroscopy (NIRS) technology in urology were published in the October 2008 edition of the prestigious Canadian Journal of Urology with the launch of a special issue devoted to "Invention, Innovation and Evocation".

In back-to-back articles, Andrew J. Macnab, MD and Lynn Stothers, MD of The University of British Columbia Department of Urological Sciences and UBC Hospital Bladder Care Centre describe the application of NIRS technology in urology. The first article, entitled "Development of a near-infrared spectroscopy instrument for applications in urology", reports on the feasibility of urological monitoring with NIRS instrumentation and the potential diagnostic value of the technology.

The second article, "Near-infrared spectroscopy: validation of bladder-outlet obstruction assessment using non-invasive parameters" presents the results of a study of 70 male patients with lower urinary tract symptoms (LUTS) who underwent uroflow and urodynamic pressure flow studies with simultaneous transcutaneous NIRS monitoring and measurement of post residual volume (PVR) via ultrasound. The article concludes that the NIRS algorithm is able to correctly identify more than 85% of subjects classified as obstructed using catheter urodynamics.

In an accompanying editorial article, Editor-in-Chief Gabriel P. Haas, MD, FACS stated, "The utility of this technique for evaluation of bladder outlet obstruction is but the tip of the iceberg. It is a new modality waiting for widespread utilization."

Barry Allen, President and CEO of Urodynamix Technologies, commented, "We believe that these studies, published in a premier peer-reviewed urology journal, are an important milestone in the future clinical acceptance of NIRS among urologists."

Abstracts of the articles are available on the Canadian Journal of Urology website, http://www.canjurol.com. The full text articles are also available to interested parties at the same Internet address.

About Urodynamix Technologies Ltd.

Urodynamix Technologies is a Canadian medical device company developing and commercializing non-invasive medical technology based on proprietary applications of near-infrared spectroscopy (NIRS). The Company is currently focused on products that aid in the diagnosis and treatment of urinary incontinence, lower urinary tract symptoms, prostate cancer, benign prostatic hyperplasia, and traumatic increases in intra-abdominal pressure that cause abdominal compartment syndrome. Urodynamix's breakthrough medical technology has the potential to beneficially affect more than 200 million people worldwide.

Certain information contained in this press release may be forward-looking and is subject to unknown risks, which could cause actual results to differ materially from those set forth or implied herein. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Contact Information